At a glance
ClinicalIndex Comparison RecordN/ACompleted· 62 enrolled
Drug / intervention
Princess® VOLUME Lidocainedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open-label, Multicenter, Post-market Study Evaluating Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds
In Brief
A clinical study evaluating Princess® VOLUME Lidocaine for Nasolabial Fold, Hypoplastic. Completed, enrolled 62 participants across 3 sites.
Detailed Summary
In this study, eligible subjects with moderate to severe nasolabial folds will be treated with Princess® VOLUME Lidocaine and will return for follow-up assessments 2, 4, 24 and 36 weeks after the treatment. A Touch-up treatment may be done at Week 2, if deemed appropriate by the investigator.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasolabial Fold, Hypoplastic
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedFeb 2017
Primary CompletionJul 2017
Study CompletionOct 2017
TodayJul 2026
First PostedFeb 13, 2017
Enrollment StartDec 27, 2016
Primary CompletionJul 18, 2017
Study CompletionOct 17, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.4 years ago
Interventions
Princess® VOLUME Lidocainedevice
Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable